Last reviewed · How we verify
CS1 Administration
At a glance
| Generic name | CS1 Administration |
|---|---|
| Sponsor | Cereno Scientific AB |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients (PHASE2)
- CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma (PHASE1)
- Effect of CS1 in Subjects With Pulmonary Arterial Hypertension (PHASE2)
- Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma (EARLY_PHASE1)
- CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma (PHASE1)
- Safety and Efficacy of Continued CS1 Treatment of Patients With Pulmonary Arterial Hypertension
- Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma (PHASE1, PHASE2)
- A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CS1 Administration CI brief — competitive landscape report
- CS1 Administration updates RSS · CI watch RSS
- Cereno Scientific AB portfolio CI